Syrris Atlas has the Midas Touch with Nanoparticles
News Oct 16, 2014
Midatech’s CEO, Justin Barry, explained: “Midatech is a clinical stage biotechnology company focused on translating its proprietarygold nanoparticle drug delivery platform into effective nanomedicines targeting currently unmet medical needs."
"We begin by producing functionalized gold nanoparticles on a bench scale, then move to larger scale manufacturing processes, where it makes sense to use a reactor system. Our Atlas Potassium reactors, with pH control and an Atlas Syringe Pump XL, have allowed us to scale¬up production, enabling variables such as pH and temperature to be tightly controlled.”
“The Atlas Potassium was the only logical way to move from manufacturing nanoparticles on a laboratory scale to a mini production environment. It is a reliable and reproducible reactor system that is well assembled, compact and portable, and performs exactly as we were told it would."
"Atlas Potassium is also very flexible, accommodating volumes ranging from 50 ml to 2 liters, and its operating software works well, enabling a series of validation runs to be performed quickly and easily. The Atlas reactors were easy to implement in the laboratory, and it took just six to eight months to establish a validated process. We are very happy with them.”
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Improving Pharmaceuticals: Catalyst Specifically Tuned to Integrate Fluorine AtomsNews
In the race to create more potent and stable medicines, scientists know that adding fluorine can improve drug molecules. However, there is only one fluorination reaction known to occur in nature which is performed by complex and highly specialized enzymes that are difficult to replicate. Now, scientists have developed a new, streamlined molecule that can do the work of enzymes but be designed and controlled minutely.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018